Credo Biomedical is one of the 12 finalists that have been selected to showcase during the Animal Health Innovation Summit in Hong Kong.
Online PR News – 17-October-2018 – Singapore – October 17, 2018 - Credo Biomedical Pte. Ltd., a groundbreaking molecular diagnostic company, announced today they will present at the Animal Health Innovation Summit in Hong Kong that will take place on 24th and 25th October 2018. Credo Biomedical is one of the 12 finalists that have been selected to showcase.
The Animal Health Innovation Summit is dedicated to showcasing to investors the most innovative emerging animal health companies covering the companion, aquaculture and production animal space. During the Innovation Showcase emerging and innovative organizations will pitch their company in front of a room of industry experts and investors.
Over 40 start-up animal health companies were nominated, out of which 12 companies were selected. Credo Biomedical is one of the 12 finalists.
Credo Biomedical will be introducing the CREDO CUBE, its revolutionary point-of-care molecular diagnostic solution. Using a proprietary Real Time PCR technology, the CREDO CUBE is an affordable, user friendly and reliable solution that provides diagnostic results in only 15 to 25 minutes from a variety of sample types (feces, blood, oral fluid, etc.).
About Credo Biomedical Pte. Ltd.
Credo Biomedical develops, and manufactures innovative, cost-effective, and rapid Molecular Diagnostic solutions at the Point-of-Care (POC) in the areas of Animal Health, Human Health, and Human Wellness. By providing the right information, at the right time, and to the right people, we can improve the lives of billions of people and animals around the world.